February 14, 2017 - The case was voluntarily dismissed.

December 16, 2016 - An investor in shares of Abeona Therapeutics Inc (NASDAQ: ABEO) filed a lawsuit in the U.S. District Court for the Southern District of New York over alleged violations of Federal Securities Laws by Abeona Therapeutics Inc in connection with certain allegedly false and misleading statements made between June 22, 2015 through December 9, 2016.

According to the complaint the plaintiff alleges on behalf of purchasers of PlasmaTech Biopharmaceuticals Inc securities from March 31, 2015 through June 19, 2015 and/or Abeona Therapeutics Inc (NASDAQ: ABEO) from June 22, 2015 through December 9, 2016, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that the defendants made false and/or misleading statements and/or failed to disclose that the science behind Abeona Therapeutics Inc’s proposed gene therapy treatment for Sanfilippo syndrome is unviable, that Steven H. Rouhandeh, Abeona Therapeutics Inc’s Executive Chairman and Principal Executive Officer, previously worked in a high ranking position for a biotech promoter who was convicted of securities fraud and involved in manipulating biotech stocks, and that as a result, defendants’ statements about Abeona Therapeutics Inc’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Dallas, TX based Abeona Therapeutics Inc, formerly PlasmaTech Biopharmaceuticals Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. Shares of Abeona Therapeutics Inc (NASDAQ: ABEO) grew to as high as $8.70 per share in late October 2016.

On December 12, 2016, analyst firm Mako Research published a report on Abeona Therapeutics Inc asserting, among other things, that Abeona Therapeutics Inc’s science underpinning its gene therapy approach is unviable. The report also alleged that Steven H. Rouhandeh, Abeona Therapeutics Inc's Executive Chairman and Principal Executive Officer, was a former managing director at D. Blech & Co. brokerage firm, which was the subject of a SEC investigation in the 1990s, and a securities class action that reached $15 million settlement for investors, based on allegations that D. Blech & Co artificially manipulated the price of various biotech stocks and maintained the market price of the biotech stocks to keep its company's interest in the stocks afloat.

Shares of Abeona Therapeutics Inc (NASDAQ: ABEO) declined on December 13, 2016, to as low as $4.2 per share.

On December 16, 2016, Abeona Therapeutics Inc (NASDAQ: ABEO) shares closed at $4.50 per share.